Quebec's COVID-19 vaccine plan runs contrary to new federal guidelines

Henrietta Strickland
January 14, 2021

Clinical trials for the Pfizer-BioNTech and Moderna vaccines showed the first dose provided some protection against serious illness from COVID-19.

The authorisation, as per the ordinary approvals procedure, comes after a rolling submission of data and the totality of scientific evidence submitted by Moderna.

Canada's national panel of vaccine experts says the second COVID-19 vaccine dose can be delayed briefly in a bid to get more people a first dose faster.

The company noted that the first deliveries should commence in Switzerland next week.

Johnson & Johnson is on track to roll out its single-shot coronavirus vaccine in March, and plans to have clear data on how effective it is by the end of this month or early February, the usa healthcare company's chief scientific officer said. The study is ongoing, but the protection has lasted 71 days so far.

The vaccine so far holds authorisation in the US, Canada, Israel, the European Union and the UK. Trudeau indicates that Canada will have enough supply to vaccinate up to 20-million people by June.

Given that the United States is already administering roughly 1 million doses a day, that would be an easy target and put the Americans at more than 35% of their population.

In November, the US Food and Drug Administration had authorised antibody combination for emergency use for treating mild to moderate Covid-19 in adults and paediatric patients aged 12 years at high risk for advancing to severe Covid-19 and hospitalisation.

Almost 65,000 doses of the Moderna vaccine arrived in Germany on Monday and were being kept at a military facility in Quakenbrueck in the west of the country.

The vaccine candidate inactivated whole virus particles of SARS-CoV-2 with high S-protein density and two adjuvants, alum and CpG 1018.

Other reports by Click Lancashire

Discuss This Article